Key regions: Germany, United States, India, Japan, United Kingdom
The market for Anti-Rheumatic Drugs in Serbia has been experiencing a steady growth in the past few years.
Customer preferences: The increasing prevalence of rheumatoid arthritis and other autoimmune diseases has led to a rise in demand for Anti-Rheumatic Drugs in Serbia. Patients are now more aware of the benefits of early diagnosis and treatment, which has resulted in a higher demand for these drugs. Additionally, the availability of a wide range of Anti-Rheumatic Drugs in the market has given patients the option to choose the most suitable medication for their condition.
Trends in the market: One of the major trends in the Anti-Rheumatic Drugs market in Serbia is the increasing use of biologic drugs. These drugs are highly effective in treating rheumatoid arthritis and other autoimmune diseases, and are becoming increasingly popular among patients. Another trend in the market is the growing preference for combination therapy. Patients are now opting for a combination of drugs to manage their condition, which has resulted in an increase in the sales of these drugs.
Local special circumstances: Serbia has a high prevalence of rheumatoid arthritis and other autoimmune diseases, which has resulted in a higher demand for Anti-Rheumatic Drugs. Additionally, the government has implemented policies to improve access to healthcare, which has resulted in more patients seeking treatment. The availability of affordable generic drugs has also contributed to the growth of the Anti-Rheumatic Drugs market in Serbia.
Underlying macroeconomic factors: The growth of the Anti-Rheumatic Drugs market in Serbia can be attributed to several macroeconomic factors. The increasing healthcare expenditure by the government has resulted in better access to healthcare services. Additionally, the growth of the pharmaceutical industry in the country has led to the availability of a wide range of drugs in the market. The increasing disposable income of the population has also contributed to the growth of the market, as patients are now able to afford the high cost of these drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
